26 November 2025

Expanded Relationship with GE Healthcare

Enlitic, Inc. (ASX: ENL) ("the Company") is pleased to announce an expansion of its ongoing collaboration with GE Healthcare. This expanded engagement represents a further strengthening of the partnership between the companies, reflecting GE Healthcare's continued confidence in Enlitic's technology and expertise in medical imaging data management and migration.

The new scope of work adds to the existing migration program already underway and is expected to provide additional one-off revenue over the next 12 months of approximately US$1 million. This additional work broadens the application of Enlitic's solutions within GE Healthcare and underscores the strategic importance of the partnership to both organizations.

As a result of this expansion, Enlitic will temporarily reallocate resources to support this high-priority initiative. Consequently, there are revised migration timelines, which have been acknowledged and agreed upon by GE Healthcare. Both companies are working collaboratively to optimize schedules and ensure the delivery of all contracted milestones with the highest quality and reliability.

"This expanded relationship with GE Healthcare is a strong endorsement of the value and trust we've built," said Michael Sistenich, CEO of Enlitic. "It not only increases the scope of our collaboration but also deepens our integration with one of the world's leading healthcare technology providers."

Enlitic remains focused on executing this expanded engagement effectively while continuing to deliver value to all partners and stakeholders.

We look forward to meeting with current and prospective customers and partners at the annual RSNA (Radiology Society of North America) Conference in Chicago, Illinois between November 30-December 4, 2025 to further announcements with our customers and the industry. Enlitic, will be at RNSA North Hall on Booth 7730.

– ENDS –

This announcement was authorised for release by the Board of Enlitic, Inc.

Enquiries

Enlitic Investor Relations
Australia:
invest_au@enlitic.com

About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers. Enlitic's products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com.

Enlitic's CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement.